In one group, treatment was started in 12 patients of T1DM with glargine insulin treatment, which resulted in decreased levels of IGFBP-3 nocturnally, with increased levels of IGF-1 and improved levels of HbA1c compared to insulin protamine Hagedorn insulin. The gene discussed is IGFBP3; the disease is type 1 diabetes mellitus.